Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary: Dr. Lal Path Labs Ltd.** Dr. Lal Path Labs faces critical compliance exposure under SEBI BRSR Core Expansion requirements, with a perfect 10.0/10 compliance risk score and estimated remediation costs of ₹4–14 crore—material against ₹2,351.6 crore revenue. The company's EPR (Extended Producer Responsibility) obligation status remains unconfirmed despite 6.5/10 exposure risk, creating regulatory uncertainty; diagnostics labs generate medical waste requiring statutory EPR compliance under India's Biomedical Waste Management Rules, with potential penalties for non-compliance. Absence of reported Scope 1 and Scope 2 emissions (₹0 disclosed) contradicts sector norms for laboratory operations and suggests incomplete GHG accounting rather than zero emissions, risking SEBI enforcement action or delisting if materiality thresholds are not met in mandatory BRSR disclosures. Immediate priority: clarify EPR applicability, quantify actual emissions, and establish documented compliance protocols to mitigate enforcement risk and avoid capital market penalties.
Source: Dr. Lal Path Labs Ltd. BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.